IPROVE Innovation Partnership for a Roadmapon VaccinesinEurope

Transcription

1 IPROVE Innovation Partnership for a Roadmapon VaccinesinEurope

2 IPROVE IN BRIEF What is IPROVE? Whydo we need IPROVE? IPROVE in actions (How?) Partnership (Who?)

3 WHAT An EU project (FP7) financed by the European Commission and running for 2-years from December 2013 to November 2015, budget of EUR 496,000 (Coordination & Support Action) Four leading European organisation in the vaccine field: Vaccines Europe (VE/EFPIA) European Vaccine Initiative (EVI) Sclavo Vaccines Association (SVA) European Infrastructure for Translational Medicine (EATRIS) Goal: Establish a coordinated and comprehensive European vision on gaps, needs, and priorities to spur vaccine innovation in Europe, analysing the entire value chain implementing a joined-up participatory stakeholder consultation process (TOOL). Deliverable: ROADMAP

4 WHY Europe s traditional lead in the vaccine sector in decline Traditional R&D model becoming the less and less viable and need to put in place the appropriate push and pull mechanisms to drive innovation Disparate and uncoordinated R&D agendas and need to breakdown silos in the EU vaccine R&D landscape, mobilise and pool the available yet fragmented expertise across centres of excellence and foster the establishment of vaccine innovation agenda: Consensus on priority R&D and technologies to address unmet needs Efficiency & effectiveness of funding at EU & Member State level Framework conditions needed (political, financial, regulatory) Efficiency & effectiveness of funding at EU & Member State level Need to maintain traditional EU leadership in the sector vs. other regions

5 GOAL Produce through a bottom-up approach a strategic plan shaped as a roadmap that gives clear vision, direction and impetus to policy-makers, public and private funders/investors, programming bodies at both EU and national level Translate into Policies Programmes Funding instruments Projects Novel models of collaboration

6 HOW Governance European Commission (DG R&I) Steering Committee (1 rep from each partner) Coordinator (Vaccines Europe) Affiliated members (stakeholders) Advisory Board (5 independent experts) WP1 Management & coordination WP2 Identification stakeholders and activities WP3 Consultation WP4 European strategic roadmap WP5 Communication & dissemination

7 HOW HOW Work Governance Plan (WPs)

8 HOW Consultation Pillars (WP3) Vaccine SMEs needs (May 2014) 2. Training & Communications (October 2014) 3. Infrastructures and structural needs (December 2014) 4. Innovation in R&D, Production, and Delivery (January 2015) 5. Therapeutic vaccines (March 2015) FINAL IPROVE ROADMAP (September 2015)

9 Contacts Karam Adel Ali Vaccines Europe Project Coordinator Florence Bietrix EATRIS Communications leader

10 Thank You

11 Acknowledgment This project has received funding from the European Union s Seventh Framework Programme for research, technological development and demonstration under grant agreement no

12 WHO (1/4) VE is a specialised vaccine industry group operating within the European Federation of Pharmaceutical Industries and Association (EFPIA), hereinafter referred to as VE/EFPIA. VE/EFPIA represents all the major research-based global vaccine companies as well as small and medium-sized enterprises operating in Europe. Companies represented are involved in research and development (R&D), clinical trials, production and marketing of vaccines VE/EFPIA aims to: foster a favorable policy climate for the vaccine industry in Europe to facilitate availability and access to new and innovative vaccines worldwide; create a supportive environment for improved vaccine protection, innovative vaccine development and improved coverage throughout life in the interest of individuals and community; support vaccine R&D through innovative vaccine applications.

13 WHO (2/4) Leading European Product Development Partnership (PDP) supporting the development of effective, accessible, and affordable vaccines against diseases of poverty. EVI contributes to the global efforts to control these diseases in three main ways: by providing financial, operational and managerial support to the development and clinical assessment of vaccine candidates; by promoting affordability and accessibility of vaccines in low-income populations; and by aligning all major stakeholders to ensure the successful development of vaccines for diseases of poverty for low-income populations. EVI is the coordinator of TRANSVAC ( the FP7 pan-european vaccine infrastructure project.

14 WHO (3/4) SVA is a non-profit association whose main objective is scientific research targeted towards the discovery and study of advanced immunization technologies with the aim of contributing to the innovative development of safe, effective prophylactic and therapeutic vaccines. SVA members represent European leading research organisations. SVA is the coordinator ADITEC ( the High Impact collaborative FP7 research program that aims to accelerate the development of novel and powerful immunization technologies for the next generation of human vaccines.

15 WHO (4/4) EATRIS is an ERIC (European Research Infrastructure Consortium) since December It is composed of 69 academic institutions of excellence in translational research The EATRIS vaccines platform provides the critical expertise and infrastructure in translational vaccinology to advance candidates up to phase IIa trials. It includes 10 centers of excellence in the vaccines field.